PRESS RELEASE 2020

• Ferring appoints Mirjam Mol-Arts to Executive Committee

Ferring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.

• Ferring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an amount of CHF 270 million

Ferring Pharmaceuticals announced the successful launch of its inaugural Swiss Franc Bond offering for a benchmark amount of CHF 270 million. This inaugural senior unsecured bond transaction issued by Ferring Holding SA has a fixed coupon rate of 1.05% per annum.

• Ferring and Igenomix collaborate to advance care in reproductive medicine and maternal health

Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.

• Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births

Ferring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section. Every year, 14 million women experience excessive bleeding after birth, also known as postpartum haemorrhage…

• Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its clinical…

• Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

Rebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy…

• Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years

Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW)…